Pivotal Cohorts News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pivotal cohorts. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pivotal Cohorts Today - Breaking & Trending Today

Sequana Medical NV: Sequana Medical announces 2020 Full Year Results and 2021 Outlook

Sequana Medical NV: Sequana Medical announces 2020 Full Year Results and 2021 Outlook
March 2021 07:00 CET
POSEIDON - positive interim results in Q4 2020; additional interim results expected in Q2 2021 and primary endpoint in Q2 2022
RED DESERT - positive interim results in Q4 2020; top-line data expected in Q2 2021
Successful equity placements extend cash runway into Q2 2022
Conference call with live
Ghent, BELGIUM - 17 March 2021
- Sequana Medical NV (Euronext Brussels: SEQUA, the Company ), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces its financial results for the year ended 31 December 2020, and provides a business update and an outlook for the remainder of 2021. ....

United States , James Udelson , Peter Dhondt , Cian Crosbie , Gijs Klarenbeek , Michael Felker , Guillaume Van Renterghem , Information Technology , Yale University School Of Medicine , Euronext Brussels , Chief Executive Officer , Sequana Medical , North America , North American , Pivotal Cohort , Opinion Leader , Yale University School , Chief Medical Officer , Senior Medical , Heart Failure Scientific Advisors , Direct Sodium Removal , Pivotal Cohorts , Roll In Cohort , Not Meaningful , Medical Devices Regulation , Annual Report ,

Investegate |Sequana Medical NV Announcements | Sequana Medical NV: Sequana Medical announces 2020 Full Year Results and 2021 Outlook

POSEIDON – positive interim results in Q4 2020; additional interim results expected in Q2 2021 and primary endpoint in Q2 2022
RED DESERT – positive interim results in Q4 2020; top-line data expected in Q2 2021
Successful equity placements extend cash runway into Q2 2022
Conference call with live
Ghent, BELGIUM – 17 March 2021
– Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces its financial results for the year ended 31 December 2020, and provides a business update and an outlook for the remainder of 2021.
Ian Crosbie, Chief Executive Officer at Sequana Medical, commented: “We made outstanding progress in 2020, delivering very promising clinical data in both our focus areas, liver disease / NASH ....

United States , James Udelson , Peter Dhondt , Cian Crosbie , Gijs Klarenbeek , Michael Felker , Guillaume Van Renterghem , Information Technology , Yale University School Of Medicine , Sequana Medical , Year Results , Euronext Brussels , Chief Executive Officer , North America , North American , Pivotal Cohort , Opinion Leader , Yale University School , Chief Medical Officer , Senior Medical , Direct Sodium Removal , Pivotal Cohorts , Roll In Cohort , Not Meaningful , Medical Devices Regulation , Annual Report ,

Sequana Medical Announces 2020 Full Year Results and 2021 Outlook

Sequana Medical Announces 2020 Full Year Results and 2021 Outlook
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United States , James Udelson , Peter Dhondt , Cian Crosbie , Gijs Klarenbeek , Michael Felker , Guillaume Van Renterghem , Information Technology , Yale University School Of Medicine , Euronext Brussels , Chief Executive Officer , Sequana Medical , North America , North American , Pivotal Cohort , Key Opinion Leader , Yale University School , Chief Medical Officer , Senior Medical , Heart Failure Scientific , Direct Sodium Removal , Pivotal Cohorts , Roll In Cohort , Not Meaningful , Medical Devices Regulation , Annual Report ,

Sequana Medical Announces 2020 Full Year Results and 2021 Outlook

Sequana Medical Announces 2020 Full Year Results and 2021 Outlook
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United States , James Udelson , Peter Dhondt , Cian Crosbie , Gijs Klarenbeek , Michael Felker , Guillaume Van Renterghem , Information Technology , Yale University School Of Medicine , Euronext Brussels , Chief Executive Officer , Sequana Medical , North America , North American , Pivotal Cohort , Key Opinion Leader , Yale University School , Chief Medical Officer , Senior Medical , Heart Failure Scientific , Direct Sodium Removal , Pivotal Cohorts , Roll In Cohort , Not Meaningful , Medical Devices Regulation , Annual Report ,

Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma

Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
Use of Corticosteroids Prior to Yescarta Infusion Has the Potential to Impact the BenefitRisk Profile Based on Data from a Cohort of ZUMA-1 Patients Response Rates Observed in New Analysis Remain Consistent with Pivotal Cohorts Kite, a Gilead Company today announced findings from a new analysis of the ZUMA-1 trial of Yescarta ® in adult patients with relapsed or refractory large B-cell lymphoma . Results …
Use of Corticosteroids Prior to Yescarta Infusion Has the Potential to Impact the Benefit/Risk Profile Based on Data from a Cohort of ZUMA-1 Patients ....

United States , Santa Monica , Foster City , Jacquie Ross , Olalekano Oluwole , Nathan Kaiser , Frank Neumann , Gilead Sciences , Vanderbilt University Medical Center , Drug Administration , Kite Global Head Of Clinical Development , Gilead Sciences Inc , International Blood Marrow Transplant Research , Exchange Commission , Gilead Company , Gilead Public Affairs , Gilead Company Nasdaq , Corticosteroids Prior , Yescarta Infusion Has , Risk Profile Based , Response Rates Observed , New Analysis Remain Consistent , Pivotal Cohorts , Cellular Therapy Meetings , American Society , Cellular Therapy ,